Cloning/Gene/Posterior Polymorphous corneal dystrophy

克隆/基因/后部多形性角膜营养不良

• 批准号: 6849549
• 负责人: ANTHONY John ALDAVE
• 金额: $ 16.62万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6849549
• 关键词: biotechnology; clinical research; cornea disorder; corneal endothelium; family genetics; functional /structural genomics; gene deletion mutation; gene expression; genetic disorder; genetic mapping; genetic polymorphism; genetic screening; histopathology; human genetic material tag; human subject; linkage mapping; microarray technology; polymerase chain reaction; serial analysis of gene expression

DESCRIPTION (provided by applicant): Posterior polymorphous corneal dystrophy (PPCD, PPMD, PPD; OMIM # 122000) is a dominantly inherited disorder of the corneal endothelium that is associated with a wide spectrum of clinical features and courses ranging from benign to profound visual loss from corneal swelling with or without associated glaucoma, which develops in approximately 15% of patients. PPCD has been mapped to chromosome 20p11-q11 with a maximum observed LOD score of 5.54 at theta = 0.0 with marker D20S45. Analysis of recombination events in 4 of the 21 affected patients in a single large family revealed that the PPCD gene is located in the 30 cM region between markers D20S98 and D20S108. The objective of this proposal is to identify and characterize the gene(s) responsible for PPCD. This will be accomplished as follows: 1. Better define the minimal candidate genomic region for PPCD. Perform linkage analysis in previously identified and additional new families to continue to fine map the disease locus, narrowing the candidate region, and therefore the number of candidate genes for PPCD. Examine patients with deletions in the candidate gene region of chromosome 20 for clinical features of PPCD, thereby ruling in or out candidate genes in the affected portion of the disease interval. 2. Select and prioritize candidate genes. Determine which genes are expressed in the adult human corneal endothelium. Microarray analyses (normal corneal endothelium, corneal endothelium in PPCD). Serial analysis of gene expression (SAGE). Determine which of the genes found to be expressed in the corneal endothelium map to the candidate gene region (positional approach). Analyze the function of the genes that map to the defined candidate interval, selecting those that may, when mutated, result in the clinical and histopathologic abnormalities seen in PPCD (functional approach). 3. Perform candidate gene screening. Identify sequence variants in the candidate genes. Determine whether identified sequence variants are polymorphisms or mutations. Discovery of the genetic basis of PPCD will provide a definitive means to distinguish it from other conditions with overlapping clinical features and to identify those at increased risk for vision loss from glaucoma as well as provide a greater understanding of the mechanisms of glaucoma development. Additionally, manipulation of this gene may allow researchers to induce the controlled proliferation of corneal endothelial cells in vivo or in vitro, providing an alternative to corneal transplantation for patients with an insufficient number of corneal endothelial cells to maintain corneal clarity, one of the most common indications for corneal transplantation worldwide.

描述（由申请人提供）：后部多形角膜营养不良（PPCD、PPMD、PPD; OMIM # 122000）是一种显性遗传性角膜内皮疾病，与广泛的临床特征和病程相关，从良性到角膜肿胀导致的严重视力丧失，伴或不伴相关青光眼，约15%的患者发生青光眼。PPCD已被定位到染色体20 p11-q11，在θ = 0.0处观察到的最大LOD评分为5.54，标记D20 S45。对一个大家族中21例受影响患者中4例的重组事件分析显示，PPCD基因位于标记D20 S98和D20 S108之间的30 cM区域。本提案的目的是鉴定和表征负责PPCD的基因。这将通过以下方式实现：1.更好地定义PPCD的最小候选基因组区域。在先前确定的和额外的新家族中进行连锁分析，以继续精细绘制疾病位点，缩小候选区域，从而缩小PPCD候选基因的数量。检查20号染色体候选基因区域缺失的患者PPCD的临床特征，从而排除疾病间隔受影响部分的候选基因。2.选择并优先考虑候选基因。确定哪些基因在成人角膜内皮中表达。微阵列分析（正常角膜内皮，PPCD中的角膜内皮）。基因表达系列分析（SAGE）。确定在角膜内皮中发现的表达基因中的哪一个映射到候选基因区域（位置方法）。分析映射到定义的候选区间的基因的功能，选择那些突变时可能导致PPCD中观察到的临床和组织病理学异常的基因（功能方法）。3.进行候选基因筛选。识别候选基因中的序列变异。确定识别的序列变异是多态性还是突变。PPCD的遗传基础的发现将提供一个明确的手段，以区分它与其他条件重叠的临床特征，并确定那些在增加风险的视力丧失青光眼，以及提供一个更好的理解青光眼的发展机制。此外，操纵该基因可以使研究人员在体内或体外诱导角膜内皮细胞的受控增殖，为角膜内皮细胞数量不足的患者提供角膜移植的替代方案，以维持角膜透明度，这是全球角膜移植最常见的适应症之一。